Table 1. Univariate analysis for death from prostate cancer (n=585).
|
Univariate analysis |
||||
|---|---|---|---|---|
| Variable | No. of men (deaths) | Hazard ratio (95% CI) | χ2 (1 df) | P-value |
| CCP (linear) | 585 (100) | 2.08 (1.76, 2.46) | 56.4 | 6.0 × 10−14 |
| CCP (groups) | 64.9 | 7.8 × 10−16 | ||
| ⩽0 | 194 (12) | 1 (ref.) | ||
| >0–1 | 251 (35) | 2.21 (1.15, 4.27) | ||
| >1–2 | 110 (39) | 6.84 (3.57, 13.1) | ||
| >2 | 30 (14) | 14.1 (6.48, 30.5) | ||
| Gleason score (linear) | 585 (100) | 1.89 (1.58, 2.27) | 42.2 | 8.2 × 10−11 |
| Gleason (groups) | 45.5 | 1.5 × 10−11 | ||
| 3+3 | 151 (5) | 0.20 (0.08, 0.52) | ||
| 3+4 | 200 (31) | 1 (ref.) | ||
| 4+3 | 126 (30) | 1.60 (0.96, 2.65) | ||
| >7 | 108 (34) | 2.61 (1.60, 4.26) | ||
| log(1+PSA) (ng ml−1) | 585 (100) | 2.07 (1.61, 2.65) | 34.0 | 5.6 × 10−9 |
| PSA (groups) (ng ml−1) | 32.4 | 1.2 × 10−8 | ||
| ⩽4 | 15 (4) | 4.44 (1.36, 14.4) | ||
| >4–10 | 175 (9) | 1 (ref.) | ||
| >10–25 | 210 (33) | 3.33 (1.59, 6.98) | ||
| >25–50 | 103 (28) | 6.04 (2.84, 12.8) | ||
| >50–100 | 82 (26) | 7.88 (3.69, 16.8) | ||
| Extent of disease (%) | 52.0 | 5.5 × 10−13 | ||
| <34 | 179 (10) | 0.48 (0.22, 1.02) | ||
| 34–<67 | 176 (22) | 1 (ref.) | ||
| 67–<100 | 91 (24) | 2.82 (1.56, 5.11) | ||
| 100 | 139 (44) | 3.49 (2.06, 5.93) | ||
| Age at diagnosis (years) | 585 (100) | 1.02 (0.98, 1.06) | 1.09 | 0.30 |
| Age (groups) (years) | 0.56 | 0.46 | ||
| <60 | 32 (3) | 0.42 (0.12, 1.48) | ||
| 60–64 | 57 (12) | 1 (ref.) | ||
| >64–69 | 142 (25) | 0.86 (0.43, 1.72) | ||
| >69 | 354 (60) | 0.89 (0.48, 1.66) | ||
| Year of diagnosis | 585 (100) | 0.94 (0.85, 1.04) | 1.40 | 0.24 |
| Year of diagnosis | 1.09 | 0.3 | ||
| 1999–2000 | 78 (22) | 1.33 (0.79, 2.26) | ||
| 2001–2003 | 507 (78) | 1 (ref.) | ||
| Clinical stage | 41.7 | 1.1 × 10−10 | ||
| 1 | 87 (10) | 0.71 (0.35, 1.47) | ||
| 2 | 371 (43) | 1 (ref.) | ||
| 3/4 | 127 (47) | 3.90 (2.58, 5.91) | ||
| Initial hormones | 23.8 | 1.1 × 10−6 | ||
| No | 208 (17) | 1 (ref.) | ||
| Yes | 377 (83) | 3.20 (1.90, 5.41) | ||
| CAPRA (linear) | 585 (100) | 1.40 (1.28, 1.52) | 65.0 | 7.8 × 10−16 |
| CAPRA (groups) | 64.1 | 1.2 × 10−15 | ||
| 0–2 | 80 (2) | 0.30 (0.07, 1.29) | ||
| 3–5 | 207 (16) | 1 (ref.) | ||
| 6–7 | 136 (29) | 2.90 (1.56, 5.38) | ||
| 8–10 | 162 (53) | 5.49 (3.14, 9.62) | ||
| CCR (linear) | 585 (100) | 2.17 (1.83, 2.57) | 88.9 | 4.1 × 10−21 |
| CCR (groups) | 63.4 | 1.7 × 10−15 | ||
| ⩽1 | 92 (2) | 1 (ref.) | ||
| >1–2 | 145 (10) | 3.32 (0.73, 15.2) | ||
| >2–3 | 133 (21) | 8.08 (1.89, 34.5) | ||
| >3 | 215 (67) | 18.30 (4.47, 74.6) | ||
Abbreviations: CAPRA=Cancer of the Prostate Risk Assessment; CCP=cell cycle progression; CCR=cell cycle risk; CI=confidence interval; df=degrees of freedom; ref.=reference category; PSA=prostate-specific antigen; χ2=chi-square.